NEW YORK (GenomeWeb) – Illumina said at the close of the market on Tuesday that sales of its HiSeq X Ten and NextSeq 500 instruments helped drive record revenues of $512.4 million in the fourth quarter of 2014.

During a conference call discussing the company's 2014 fourth quarter and full-year results, CEO Jay Flatley provided an update of the company's sequencing and array businesses, discussed a future liquid biopsy oncology product, and gave an update on its noninvasive prenatal testing business and progress with the US Food and Drug Administration on developing a cleared NIPT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.